Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri + vitamin d3
- Development stage
- Unknown
- Lead developer
- BioGaia
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a combination dietary supplement containing the probiotic strain Lactobacillus reuteri (specifically Limosilactobacillus reuteri DSM 17938) and vitamin D3 (cholecalciferol). The probiotic component helps maintain or restore healthy gut flora and may support gastrointestinal function and immune modulation. Vitamin D3 is essential for calcium homeostasis, bone health, and immune function. Clinical studies suggest that this combination can improve serum levels of 25(OH)D (a marker of vitamin D status), enhance gastrointestinal function in children with functional GI disorders, reduce IgE levels (suggesting an immunomodulatory effect), and may provide ancillary benefits in allergic diseases such as asthma[1][2][4][6]. The mechanism involves both direct effects of cholecalciferol on the vitamin D receptor to regulate calcium metabolism and immune responses, as well as the probiotic's ability to modulate gut microbiota composition and potentially enhance absorption of nutrients including vitamin D.
- Brand names
- BioGaia Immunity Vitamin DBioGaia Protectis BABY with Vitamin DBioGaia Reuteri Ecz-immune + D3 Probiotic
- Other names
- Limosilactobacillus reuteri DSM 17938 + cholecalciferolL. reuteri DSM 17938 + vitamin D3
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on lactobacillus reuteri + vitamin d3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri + vitamin d3.